Drug intelligence / Profile preview

CBT-199

Development stage: Unknown
Lead developer: Cloudbreak Pharma
Modality: Small Molecules
Administration: Ophthalmic

Overview

CBT-199 is a novel small molecule topical ophthalmic emulsion being developed by Cloudbreak Pharma and its subsidiary ADS Therapeutics for the treatment of presbyopia. The drug functions as a parasympathomimetic miotic agent, designed to constrict the pupil and thereby improve near vision by increasing the depth of focus. It utilizes a proprietary non-aqueous, water-free formulation to deliver the active ingredient. The program has received FDA clearance to proceed with Phase 2 clinical trials in the United States, following preclinical safety and tolerability studies conducted in China.

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on CBT-199.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBT-199.

Explore the full profile